AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
PE: At this year’s ASCO Annual Meeting, your team presented new data from both ABBV-400 and ABBV-706, both of which are ADCs. Can you discuss what the data discovered in each disease indication?
Valencia: At AbbVie, a big focus for us is in solid tumors. It’s really to tackle those diseases that have a high medical need. They’ve been treated for the last decades with good old chemotherapy, decades old chemotherapy. Despite the advances in those areas the survival rates are really low. When we think about it in an area such as colorectal cancer, for example, despite all the advances, patients with metastatic setting live no more than a year.
There’s a type of lung cancer called small cell lung cancer (SCLC) that only 3 out of 100 patients survive more than five years. When we look at those diseases, we see the unmet need and that they’re being treated with chemo. Those are the ones we get excited about and come in with our ADC portfolio to try and tackle.
Going back to ABBV-400 and ABBV-706, ABBV-400 is a next generation c-Met targeted ADC that has a topoisomerase 1 inhibitor (Top1i) payload that really tackles the cancer cells. Data was presented at ASCO, and we presented Phase I data for heavily pretreated patients. We're talking patients that had at least four to five lines of therapies before coming to ABBV-400, where, at that point, a patient doesn't have more options. The response rate for chemotherapy is in low single digits, maybe up to 5%. In these patients, ABBV-400 showed a response rate close to 20% - 24% in two doses overall. If you pick patients that have higher expression of c-Met, you saw a response rate of up to 38%, and that got us pretty excited.
We tested ABBV-706 in our first-in-human trial, with results in dose escalation included 23 SCLC patients. We saw that in escalation across multiple doses with an average of three lines of therapy, we saw benefit for all patients. We saw a response rate of about 60% in this SCLC population and then a disease control rate of more than 90%. Virtually all patients have some benefit of the drug. So, for us, that’s quite exciting in both ABBV-400 and ABBV-706.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
